Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia by genespire | Jan 20, 2026 | News
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting by genespire | May 14, 2025 | News
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA by genespire | May 8, 2025 | News
The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform by genespire | Mar 31, 2025 | News
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic by Harry Fowler | Sep 25, 2024 | News
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting by Harry Fowler | May 9, 2024 | News
